AUSTIN, Texas, Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation
(Nasdaq: LMNX) today announced the retirement of its Chairman,
G. Walter Loewenbaum, from its Board
of Directors ("Board") effective August
3, 2020.
"On behalf of Luminex's shareholders and Board, I would like to
thank Wally for his invaluable service and contributions to Luminex
for over 25 years," said Nachum 'Homi' Shamir, Luminex's President
and Chief Executive Officer. "Wally was a strong voice and guiding
hand in bringing Luminex from a small start-up, with no revenue,
operating out of one small facility in Texas; to the multi-national $400 million in expected revenue Company we see
today. We wish him the very best in his retirement and in all his
future endeavors."
"I am extremely proud of Luminex's achievements during my tenure
and have truly enjoyed my time with this board and management
team," said Mr. Loewenbaum. "Although I feel now is the best time
for me to retire, I am confident that Luminex has a strong team in
place to continue to build on its past successes and emerging
opportunities."
In connection with Mr. Loewenbaum's departure, Mr. Shamir will
assume the responsibilities of Chairman of the Board. Additionally,
the Board has determined that Dr. Edward
Ogunro will become lead independent director. Dr. Ogunro is
an accomplished executive in the Diagnostics business, having held
a number of leadership positions for more than 20 years at Abbott
Laboratories, and served as Senior Vice President, R&D and
Medical Affairs and Chief Scientific Officer of Hospira, Inc. He
has directly relevant technical and operational industry experience
in the diagnostics and medical device industry that has allowed him
to be highly effective chairing our Strategy and Development
Committee.
Upon Mr. Loewenbaum's retirement, Luminex's Board of Directors
will consist of eight members: Mr. Shamir, Dr. Ogunro, Tom Erickson, Kevin
McNamara, Jim Kever,
Ken Samet, Dr. Stephen Eck and Dijuana
Lewis.
About Luminex Corporation
At Luminex, our mission is to empower labs to obtain reliable,
timely, and actionable answers, ultimately advancing health. We
offer a wide range of solutions applicable in diverse markets
including clinical diagnostics, pharmaceutical drug discovery,
biomedical research, genomic and proteomic research, biodefense
research, and food safety. We accelerate reliable answers while
simplifying complexity and deliver certainty with a seamless
experience. To learn more about Luminex, please visit us at
luminexcorp.com.
Contacts
Harriss Currie
Senior Vice President,
Chief Financial Officer
hcurrie@luminexcorp.com
512-219-8020
Carla Stanaford
Investor Relations
cstanaford@luminexcorp.com
937-469-2120
Media Contact:
Michele Parisi
Bioscribe
mparisi@bioscribe.com
925-864-5028
View original content to download
multimedia:http://www.prnewswire.com/news-releases/luminex-corporation-announces-departure-of-g-walter-loewenbaum-from-its-board-of-directors-301105971.html
SOURCE Luminex Corporation